last
year
increas
intern
travel
intensifi
avail
lowcost
flight
facilit
movement
increas
number
patient
area
endem
diseas
distant
region
consequ
citi
around
flight
hub
expos
rapid
dissemin
import
infect
report
initi
dissemin
hiv
infect
north
america
recent
influenza
pandem
similarli
outbreak
cholera
report
travel
long
distanc
flight
tourism
also
associ
dissemin
infect
measl
rubella
diphtheria
typhoid
fever
chicken
pox
addit
malaria
haemorrhag
fever
poor
health
condit
crowd
associ
tuberculosi
tb
diarrhoea
tetanu
infecti
event
may
import
migrant
area
devast
war
immunocompromis
patient
encompass
grow
popul
increas
suscept
infecti
complic
live
longer
better
qualiti
life
ever
may
opportun
travel
potenti
encount
travelassoci
infect
estim
one
third
solidorgan
transplant
sot
recipi
may
travel
resourcelimit
countri
within
first
year
posttranspl
survey
north
american
transplant
centr
haematopoiet
stem
cell
transplant
hsct
recipi
report
travel
outsid
usa
canada
transplant
intern
journal
infecti
diseas
signific
number
immunocompromis
patient
may
also
migrant
may
return
countri
origin
visit
friend
rel
may
acquir
travelassoci
infect
increas
use
monoclon
antibodi
therapi
immunolog
oncolog
diseas
creat
anoth
atrisk
popul
although
actual
risk
travelassoci
infect
patient
well
establish
data
real
risk
infect
immunocompromis
travel
rel
gener
travel
popul
scarc
particularli
risk
develop
ill
sever
enough
warrant
admiss
intens
care
unit
icu
repatri
immunocompromis
patient
hospit
destin
countri
also
carri
risk
contamin
receiv
hospit
multidrugresist
mdr
microorgan
requir
specif
infect
control
measur
articl
also
address
certain
specif
syndrom
pneumonia
acut
respiratori
distress
syndrom
ard
occur
travel
posit
paper
second
escmid
consensu
document
subject
aim
provid
intensivist
infecti
diseas
specialist
emerg
physician
standard
approach
manag
seriou
travelrel
infect
icu
emerg
depart
document
cooper
effort
member
two
european
societi
clinic
microbiolog
infecti
diseas
escmid
studi
group
coordin
hakan
leblebicioglu
jordi
rello
esgitm
escmid
studi
group
infect
travel
migrant
esgcip
escmid
studi
group
infect
critic
ill
patient
respect
relev
expert
subject
section
prepar
first
draft
edit
approv
addit
member
escmid
studi
group
articl
summar
consider
regard
clinic
syndrom
requir
icu
admiss
travel
cover
immunocompromis
patient
tabl
risk
infect
sot
recipi
vari
accord
multipl
factor
name
type
organ
transplant
time
transplant
type
dose
immunosuppress
drug
receiv
first
month
posttranspl
infecti
complic
mainli
healthcareassoci
profound
immunosuppress
occur
month
histor
period
opportunist
infect
diagnos
includ
herpesviru
infect
cytomegaloviru
pneumocysti
jirovecii
pneumonia
invas
fungal
infect
howev
use
univers
antivir
prevent
strategi
longterm
cotrimoxazol
prophylaxi
opportunist
infect
current
rare
seen
month
risk
infect
decreas
significantli
infect
period
usual
communityacquir
except
case
increas
immunosuppress
due
allograft
reject
dysfunct
case
chronic
surgic
complic
incid
infect
higher
earli
transplant
recommend
avoid
travel
first
year
hsct
recipi
increas
risk
bacteri
fungal
infect
engraft
period
first
month
posttranspl
case
graftversushost
diseas
cellular
immunosuppress
mechan
respons
develop
viral
infect
particularli
cytomegaloviru
adenoviru
bk
viru
invas
fungal
infect
second
year
posttranspl
consid
degre
immunosuppress
nonsignific
patient
develop
chronic
complic
use
biolog
agent
therapi
rheumatolog
autoimmun
diseas
increas
consider
recent
year
data
risk
infect
mainli
limit
use
antitumour
necrosi
factor
tnf
agent
sever
larg
cohort
studi
found
patient
receiv
antitnf
therapi
greatest
risk
develop
skin
infect
although
overal
risk
sever
infect
similar
patient
receiv
nonbiolog
therapi
studi
netherland
assess
risk
infect
travel
receiv
biolog
agent
rel
travel
companion
immunocompromis
patient
significantli
higher
risk
develop
skin
infect
fatigu
abdomin
pain
fever
diarrhoea
respiratori
infect
note
seriou
infect
develop
trip
patient
patient
antitnf
therapi
increas
risk
develop
mycobacteri
infect
sever
case
dissemin
tb
fatal
outcom
report
literatur
cutan
leishmaniasi
also
report
patient
antitnf
treatment
risk
bacteri
fungal
infect
patient
oncolog
condit
increas
administr
chemotherapi
andor
radiotherapi
andor
immunotherapi
particularli
period
neutropenia
contrast
risk
infect
gener
consid
increas
month
conclus
chemotherapi
patient
receiv
hormon
therapi
patient
haematolog
condit
lymphoma
hodgkin
diseas
may
howev
degre
cellular
immunosuppress
even
month
remiss
diseas
asplen
patient
significantli
higher
risk
infect
encapsul
bacteria
name
streptococcu
pneumonia
neisseria
meningitidi
haemophilu
influenza
capnocytophaga
canimorsu
thu
appropri
vaccin
conjug
vaccin
essenti
prevent
strategi
patient
potenti
lifethreaten
infect
common
asplen
patient
includ
salmonellosi
babesiosi
malaria
risk
infect
higher
first
month
follow
splenectomi
increas
risk
persist
year
risk
infect
asplen
patient
depend
underli
condit
higher
patient
haematolog
diseas
immun
may
fulli
success
associ
suboptim
protect
long
period
time
patient
may
instruct
start
empir
antibiot
target
encapsul
bacteria
immedi
clinic
sign
symptom
infect
ensu
studi
address
epidemiolog
clinic
manifest
malaria
immunocompromis
patient
incid
malaria
report
less
hsct
recipi
endem
countri
pakistan
howev
data
immunosuppress
condit
travel
miss
despit
lack
prospect
studi
appear
malaria
associ
sever
outcom
immunocompromis
patient
gener
popul
recent
systemat
review
found
publish
case
malaria
sot
recipi
least
one
criterion
sever
malaria
manuel
person
commun
importantli
malaria
may
develop
transmiss
organ
donor
may
travel
histori
case
cerebr
malaria
parasitemia
report
patient
receiv
infliximab
howev
sever
diseas
occur
patient
biolog
well
malaria
also
sever
splenectom
patient
due
lack
clearanc
intraerythrocyt
parasit
success
treatment
sever
malaria
immunocompromis
patient
report
use
erythropheresi
artesun
choic
prevent
strategi
malaria
immunocompromis
travel
individu
favour
antimalari
prophylaxi
patient
travel
intermediaterisk
highrisk
region
sever
case
sever
dengu
immunocompromis
patient
report
mostli
patient
endem
countri
seri
kidney
transplant
recipi
india
patient
diagnos
dengu
sever
cours
die
present
fever
thrombocytopenia
myalgia
retroocular
pain
contrast
seri
eight
patient
receiv
biolog
diagnos
dengu
none
develop
sever
infect
dengu
fever
report
frequent
caus
febril
neutropenia
haematolog
patient
india
associ
wors
outcom
earli
diagnosi
essenti
immunocompromis
travel
clinic
manifest
suggest
dengu
order
initi
earli
appropri
support
therapi
aggress
volum
replac
within
first
h
icu
admiss
import
limit
develop
multipl
organ
dysfunct
syndrom
increas
probabl
surviv
travelrel
fungal
infect
immunocompromis
patient
uncommon
potenti
associ
sever
cours
increas
mortal
invas
travelrel
fungal
infect
manifest
sever
cours
sot
recipi
hivinfect
individu
includ
dissemin
penicillium
marneffei
infect
aspergillosi
histoplasmosi
coccidioidomycosi
patient
receiv
monoclon
antibodi
sever
travelassoci
histoplasmosi
associ
mortal
rate
anoth
report
malign
risk
factor
acquir
cryptococcu
gattii
infect
importantli
infect
may
long
incub
period
travel
histori
may
underreport
detail
travel
histori
sought
immunocompromis
travel
develop
fever
associ
pulmonari
lesion
andor
local
cutan
subcutan
diseas
patient
investig
promptli
aggress
diagnosi
invas
fungal
infect
risk
tb
increas
transplant
patient
hivinfect
individu
patient
receiv
biolog
risk
travelacquir
tb
immunocompromis
patient
well
establish
screen
latent
tb
infect
travel
endem
region
patient
might
howev
identifi
patient
risk
develop
activ
tb
leptospirosi
common
caus
fever
return
travel
associ
sever
complic
seri
nine
hivinfect
patient
leptospirosi
present
sever
sepsi
mortal
data
sever
leptospirosi
immunocompromis
popul
lack
nocardiosi
sot
recipi
associ
high
incid
dissemin
diseas
particularli
central
nervou
system
involv
strongyloidiasi
immunocompromis
patient
rare
potenti
lifethreaten
condit
donorderiv
travelacquir
infest
strongyloid
stercorali
associ
high
mortal
case
chaga
diseas
trypanosoma
cruzi
either
consequ
reactiv
latent
infect
identifi
time
transplant
unrecord
travel
histori
stay
endem
area
transmiss
organ
donor
also
associ
high
mortal
furthermor
immunocompromis
patient
may
particularli
suscept
sever
form
west
nile
viru
infect
tickborn
enceph
activ
sought
workup
patient
central
nervou
system
symptom
return
endem
area
also
case
report
sever
diseas
travelassoci
infect
salmonellosi
vibrio
parahaemolyticu
viscer
leishmaniasi
immunocompromis
patient
mani
caus
respiratori
failur
ard
specif
certain
geograph
region
may
appear
unexpectedli
travel
less
common
nevertheless
extrem
import
appropri
therapi
requir
correct
diagnosi
infect
may
epidem
potenti
infecti
caus
particular
may
recogn
immedi
may
usual
geograph
context
caus
ard
discuss
briefli
tabl
summar
main
recommend
antimicrobi
regimen
specif
organ
involv
ard
return
travel
cap
like
caus
acut
respiratori
failur
return
travel
usual
pathogen
pneumonia
h
influenza
mycoplasma
pneumonia
chlamydophila
pneumonia
legionella
pneumophila
virus
influenza
respiratori
syncyti
viru
common
culprit
howev
aspir
must
consid
elderli
becom
inebri
whilst
holiday
less
common
pathogen
staphylococcu
aureu
avian
influenza
virus
middl
east
respiratori
syndrom
coronaviru
merscov
gramneg
rod
burkholderia
pseudomallei
must
also
consid
well
pathogen
usual
caus
pneumonia
malaria
influenza
virus
current
circul
perhap
common
travelrel
infect
particularli
unvaccin
travel
across
hemispher
avail
vaccin
cover
particular
strain
effect
influenza
acut
ill
manifest
pyrexia
cough
chill
myalgia
fatigu
howev
sever
complic
specif
pneumonia
especi
pandem
year
influenza
pandem
death
report
global
estim
time
higher
primari
risk
factor
age
young
middl
age
age
year
morbid
obes
pregnanc
immunocompromis
statu
influenza
also
increas
risk
bacteri
pneumonia
particularli
caus
pneumonia
aureu
sever
diseas
deterior
acut
day
profound
hypoxemia
shock
often
multipl
organ
dysfunct
syndrom
patholog
find
intens
inflammatori
haemorrhag
pneumonia
sever
seem
influenc
presenc
absenc
associ
bacteri
cap
patient
featur
particularli
unvaccin
travel
anoth
hemispher
winter
season
investig
influenza
diagnosi
base
throat
swab
nasal
wash
commerci
kit
base
antigen
rtpcr
unfortun
low
uptak
influenza
vaccin
even
amongst
healthcar
worker
remain
larg
pool
suscept
individu
although
yet
report
transmit
human
avian
influenza
remain
potenti
threat
particularli
southeast
asia
travel
contact
bird
affect
area
present
otherwis
unexplain
ard
screen
report
countri
current
preval
egypt
staphylococcu
aureu
pneumonia
usual
fulmin
diseas
associ
rapid
onset
respiratori
failur
frequent
progress
multipl
organ
dysfunct
shock
death
complic
frequent
includ
pulmonari
necrosi
abscess
empyema
format
particularli
strain
produc
pantonvalentin
leukocidin
pvl
toxin
cytotoxin
respons
leukocyt
destruct
tissu
necrosi
risk
factor
colon
infect
aureu
preced
influenzalik
ill
ili
leucopenia
l
characterist
may
invers
biomark
pvl
burden
methicillinsensit
aureu
mssa
methicillinresist
aureu
mrsa
caus
cap
latter
primarili
problem
recognit
organ
preval
countri
standard
guidelinebas
therapi
pneumonia
cover
mrsa
sensit
profil
communityacquir
mrsa
differ
hospitalacquir
mrsa
may
suscept
macrolid
quinolon
clindamycin
trimethoprimsulfamethoxazol
therapi
consist
appropri
antimicrobi
therapi
linezolid
possibl
prefer
vancomycin
particularli
strain
pvlproduc
vancomycin
ceftarolin
pneumonia
common
present
legionnair
diseas
legionellosi
may
sever
lead
multiorgan
failur
death
characterist
clinic
find
rel
bradycardia
hyponatremia
elev
serum
creatinin
kinas
diarrhoea
confus
impair
liver
kidney
function
recommend
treatment
regimen
macrolid
fluoroquinolon
ten
year
sever
acut
respiratori
syndrom
sar
epidem
affect
almost
peopl
caus
death
merscov
new
coronaviru
famili
appear
saudi
arabia
subsequ
spread
nine
countri
near
arabian
peninsula
countri
elsewher
march
world
health
organ
global
case
count
laboratoryconfirm
case
death
case
resid
travel
middl
east
saudi
arabia
contact
travel
return
area
merscov
differ
sarscov
bind
differ
receptor
camel
thought
primari
reservoir
host
although
mean
transmiss
anim
poorli
understood
wherea
transmiss
occur
human
epidem
potenti
appear
less
diseas
alway
sever
symptom
rang
ili
sever
pneumonia
requir
mechan
ventil
sever
affect
patient
mostli
comorbid
diabet
renal
failur
chronic
lung
diseas
immunocompromis
specif
antivir
treatment
avail
merscov
infect
manag
primarili
support
direct
toward
prevent
respiratori
complic
infect
control
corticosteroid
current
recommend
set
still
advis
travel
middl
east
increas
risk
sever
diseas
avoid
contact
camel
secret
avoid
drink
raw
camel
milk
also
prevent
infect
brucella
travel
practic
good
hand
food
hygien
particularli
camel
present
number
gramneg
pathogen
may
caus
pneumonia
ard
particular
relat
aspir
associ
ventil
pathogen
pseudomona
aeruginosa
acinetobact
baumannii
klebsiella
pneumonia
escherichia
coli
enterobacteriacea
concern
latter
includ
extendedspectrum
betalactamas
esbl
carbapenemaseproduc
produc
new
delhi
metalloblactamas
may
acquir
medic
tourism
diagnosi
requir
high
index
suspicion
test
specif
gene
respons
enzym
product
treatment
remain
challeng
due
defici
antibiot
pipelin
burkholderia
pseudomallei
also
gramneg
bacillu
endem
southeast
asia
northern
australia
possibl
indian
subcontin
southern
china
hong
kong
taiwan
infect
result
inocul
contamin
soil
surfac
water
skin
abras
subsequ
haematogen
spread
horizont
transmiss
also
occur
well
transmiss
inhal
pollut
water
common
caus
fatal
communityacquir
bacteraemia
pneumonia
certain
area
northeastern
thailand
well
darwin
australia
travel
endem
area
especi
wet
season
particularli
comorbid
risk
variabl
diseas
sever
rang
present
pneumonia
abscess
osteomyel
arthriti
make
diagnosi
challeng
patient
present
pneumonia
may
appear
nodular
infiltr
air
space
consolid
often
septic
shock
diagnosi
made
b
pseudomallei
cultur
specif
media
requir
ceftazidim
meropenem
without
highdos
cotrimoxazol
drug
choic
although
tb
may
occur
patient
seldom
caus
respiratori
failur
short
period
time
yet
recent
prospect
studi
south
africa
report
adult
activ
tb
may
requir
mechan
ventil
refractori
hypoxemia
high
tb
preval
countri
translat
signific
burden
diseas
set
tb
suspect
confirm
tb
consid
travel
histori
involv
relev
exposur
standard
smear
microscopi
cultur
use
diagnosi
rapid
pcr
avail
genexpert
mtbrif
shown
increas
sensit
shorten
time
treatment
high
clinic
suspicion
tb
empir
therapi
initi
adequ
sampl
obtain
particularli
case
lifethreaten
dissemin
infect
initi
therapi
four
drug
isoniazid
rifampicin
pyrazinamid
ethambutol
gener
recommend
low
preval
resist
depend
patient
origin
result
rapid
detect
rpob
gene
mutat
patient
mdror
xdrtb
need
treat
secondlin
agent
includ
aminoglycosid
quinolon
paraaminosalicyl
acid
cycloserin
clofazimin
new
drug
bedaquilin
linezolid
delamanid
malaria
frequent
travelrel
diseas
may
also
lead
ard
sever
affect
patient
increas
alveolar
capillari
permeabl
may
result
pulmonari
oedema
respiratori
failur
either
present
treatment
pregnant
women
particularli
risk
slide
microscopi
rapid
antigen
test
standard
diagnost
tool
treatment
choic
parenter
artemisinin
although
resist
emerg
noninfecti
caus
bilater
pulmonari
infiltr
respiratori
failur
must
differenti
infecti
caus
includ
cardiogen
pulmonari
oedema
inflammatori
pulmonari
diseas
cryptogen
organ
pneumonia
cop
fibrosi
alveolar
haemorrhag
includ
idiopath
granulomat
polyangi
lupu
vascul
ard
condit
eosinophil
pneumonia
pancreat
inhal
injuri
trauma
identifi
clinic
expertis
critic
along
use
biomark
creactiv
protein
procalcitonin
probtyp
natriuret
peptid
serolog
exclud
autoimmun
diseas
imag
includ
echocardiographi
mechan
ventil
alon
inadequ
use
neuromuscular
blockad
recruit
techniqu
includ
prone
ventil
venoven
extracorpor
membran
oxygen
ecmo
may
improv
oxygen
outcom
berlin
classif
ard
sever
univers
accept
util
determin
site
therapi
acut
physiolog
chronic
health
evalu
apach
score
provid
addit
inform
regard
icu
hospit
outcom
pneumonia
frequent
use
score
pneumonia
sever
index
psi
evalu
mortal
risk
tb
patient
tbscore
use
shown
predict
outcom
haemorrhag
symptom
fever
caus
mani
infect
due
bacteria
virus
parasit
dissemin
intravascular
coagul
dic
may
manifest
sever
septicaemia
caus
almost
gramposit
gramneg
bacteria
dic
particularli
present
septicaemia
n
meningitidi
figur
also
seen
patient
aureu
pneumonia
bloodstream
infect
figur
numer
virus
may
also
caus
haemorrhag
symptom
includ
dengu
viru
crimeancongo
haemorrhag
fever
viru
ebola
viru
yellow
fever
viru
hanta
viru
other
tabl
import
establish
whether
patient
histori
travel
within
past
week
area
viral
haemorrhag
fever
endem
immedi
admiss
tabl
histori
clinic
featur
suggest
detail
obtain
shown
tabl
patient
evalu
whether
isol
necessari
countri
haemorrhag
fever
virus
occur
malaria
also
endem
malaria
test
rapid
diagnost
test
microscopi
perform
immedi
time
blood
cultur
bacteri
infect
obtain
malaria
exclud
treatment
start
cover
broad
rang
bacteri
infect
time
diagnosi
confirm
exampl
gangren
relat
sever
staphylococc
septicaemia
shown
figur
rapid
assess
patient
isol
key
limit
healthcareassoci
transmiss
merscov
outbreak
south
korea
illustr
rapidli
infect
spread
overcrowd
hospit
merscov
case
saudi
arabia
also
link
transmiss
hospit
case
sarscov
crimeancongo
haemorrhag
fever
train
paramed
staff
nurs
physician
well
guidelin
recognit
rapid
assess
febril
patient
initi
point
contact
essenti
isol
area
febril
patient
relev
travel
histori
dic
acquir
condit
vascular
system
lead
uncontrol
system
activ
coagul
pathway
gener
thrombin
fibrin
may
caus
thrombot
occlus
blood
vessel
henc
organ
injuri
failur
accompani
inflammatori
reaction
augment
coagul
process
dic
frequent
accompani
system
inflammatori
respons
syndrom
sir
sever
sepsi
trauma
condit
divers
anaphylaxi
heat
stroke
system
activ
clot
system
associ
consumpt
coagul
factor
platelet
variou
combin
platelet
count
prothrombin
time
activ
partial
thromboplastin
time
aptt
decreas
antithrombin
protein
c
well
plasma
level
fibrin
ddimer
use
diagnosi
standard
approach
achiev
use
score
system
intern
societi
thrombosi
haemostasi
success
therapi
dic
possibl
underli
caus
identifi
treat
substitut
coagul
factor
current
unclear
due
lack
appropri
random
placebocontrol
trial
use
antifibrinolyt
dic
avoid
drug
class
may
lead
deposit
fibrin
vascular
wall
overal
preval
dic
viral
haemorrhag
fever
high
contribut
morbid
mortal
earli
effect
treatment
viral
infect
avail
reduc
detriment
complic
dic
paramet
assess
dic
haemolysi
provid
tabl
question
ask
patient
travel
area
haemorrhag
fever
occur
patient
fever
histori
fever
previou
hour
patient
care
forcom
contact
bodi
fluid
ofhandl
clinic
specimen
blood
urin
faec
tissu
laboratori
cultur
live
dead
individu
anim
known
strongli
suspect
vhf
patient
receiv
tick
bite
andor
crush
tick
bare
hand
andor
travel
rural
environ
contact
livestock
tick
possibl
cchf
endem
area
patient
live
work
basic
rural
condit
lassa
ebola
marburg
fever
endem
ie
westcentr
africa
south
america
patient
travel
local
area
vhf
outbreak
occur
cchf
crimeancongo
haemorrhag
fever
vhf
viral
haemorrhag
fever
patient
suspect
sever
sepsi
manag
accord
standard
guidelin
includ
broadspectrum
antibiot
aggress
initi
fluid
replac
blood
pressur
support
need
correct
acidosi
oxygen
intub
mechan
ventil
need
echocardiographi
essenti
evalu
cardiac
function
veget
cardiac
valv
initi
stage
difficult
differenti
viral
haemorrhag
fever
sever
bacteri
sepsi
sever
malaria
